WHIM Study - Wesley Research Institute
Wesley Research Institute

The aim of this study is to demonstrate the efficacy of Mavorixafor in patients with WHIM syndrome.

Research Objectives





Study location

Wesley Research Institute

Study type

Industry Sponsored

Patient group

Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM Syndrome)

Industry sponsor

Sponsors: X4 Pharmaceuticals Incorporated

About this clinical trial

WHIM syndrome is a rare genetic disease of the immune system that affects the body’s immune system ability to fight off infections. Patients diagnosed with WHIM syndrome have a deficiency in specific infection-fighting antibodies in the blood and have an extremely low level of infection fighting white blood cells called neutrophils, which move from the bone marrow into the bloodstream where they can patrol and protect the body.

Mavorixafor is a drug that is intended to release certain types of white blood cells (neutrophils and lymphocytes) from the bone marrow and to raise the number of white blood cells in blood circulation.

The more of these type of white blood cells you have in your blood the better your body can fight infection and as such, may help to reduce the number and severity of your infections.

The aim of this study is to demonstrate the efficacy of Mavorixafor in patients with WHIM syndrome.

Lead investigator

  • Dr Daman Langguth

Clinical trial coordinator

  • Venita Bali

Technical title

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension (4WHIM)

This clinical trial is now closed for recruitment

If you would like more information about this trial, please complete the contact form below.

I consent to receive updates on Wesley Research Institute news and events, clinical trials, research projects and how to support WRI.
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram